Literature DB >> 23087103

cCMP, cUMP, cTMP, cIMP and cXMP as possible second messengers: development of a hypothesis based on studies with soluble guanylyl cyclase α(1)β(1).

Kerstin Y Beste1, Roland Seifert.   

Abstract

Adenosine 3',5'-cyclic monophosphate and guanosine 3',5'-cyclic monophosphate are second messengers that regulate multiple physiological functions. The existence of additional cyclic nucleotides in mammalian cells was postulated many years ago, but technical problems hampered development of the field. Using highly specific and sensitive mass spectrometry methods, soluble guanylyl cyclase has recently been shown to catalyze the formation of several cyclic nucleotides in vitro. This minireview discusses the broad substrate-specificity of soluble guanylyl cyclase and the possible second messenger roles of cyclic nucleotides other than adenosine 3',5'-cyclic monophosphate and guanosine 3',5'-cyclic monophosphate. We hope that this article stimulates productive and critical research in an area that has been neglected for many years.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23087103     DOI: 10.1515/hsz-2012-0282

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  16 in total

1.  Is cIMP a second messenger with functions opposite to those of cGMP?

Authors:  Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-07-15       Impact factor: 3.000

Review 2.  Novel protein kinase targets in vascular smooth muscle therapeutics.

Authors:  David A Tulis
Journal:  Curr Opin Pharmacol       Date:  2017-04-04       Impact factor: 5.547

3.  Report on the Third Symposium "cCMP and cUMP as New Second Messengers".

Authors:  Erich H Schneider; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-12-04       Impact factor: 3.000

4.  cCMP is a substrate for MRP5.

Authors:  Svenja Laue; Moritz Winterhoff; Volkhard Kaever; Jeroen J van den Heuvel; Frans G Russel; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-07-15       Impact factor: 3.000

5.  N4-monobutyryl-cCMP activates PKA RIα and PKA RIIα more potently and with higher efficacy than PKG Iα in vitro but not in vivo.

Authors:  Sabine Wolter; Stefan Dove; Marina Golombek; Frank Schwede; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-09-06       Impact factor: 3.000

6.  ExoY from Pseudomonas aeruginosa is a nucleotidyl cyclase with preference for cGMP and cUMP formation.

Authors:  Urike Beckert; Sabine Wolter; Christina Hartwig; Heike Bähre; Volkhard Kaever; Daniel Ladant; Dara W Frank; Roland Seifert
Journal:  Biochem Biophys Res Commun       Date:  2014-06-24       Impact factor: 3.575

Review 7.  The lost language of the RNA World.

Authors:  James W Nelson; Ronald R Breaker
Journal:  Sci Signal       Date:  2017-06-13       Impact factor: 8.192

8.  Dissociations in the effects of β2-adrenergic receptor agonists on cAMP formation and superoxide production in human neutrophils: support for the concept of functional selectivity.

Authors:  Irena Brunskole Hummel; Michael T Reinartz; Solveig Kälble; Heike Burhenne; Frank Schwede; Armin Buschauer; Roland Seifert
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

9.  Nucleotidyl cyclase activity of particulate guanylyl cyclase A: comparison with particulate guanylyl cyclases E and F, soluble guanylyl cyclase and bacterial adenylyl cyclases CyaA and edema factor.

Authors:  Kerstin Y Beste; Corinna M Spangler; Heike Burhenne; Karl-Wilhelm Koch; Yuequan Shen; Wei-Jen Tang; Volkhard Kaever; Roland Seifert
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

10.  Analysis of substrate specificity and kinetics of cyclic nucleotide phosphodiesterases with N'-methylanthraniloyl-substituted purine and pyrimidine 3',5'-cyclic nucleotides by fluorescence spectrometry.

Authors:  Daniel Reinecke; Frank Schwede; Hans-Gottfried Genieser; Roland Seifert
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.